<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Vaccine Technology on FinanClub</title>
    <link>https://finan.club/tags/vaccine-technology/</link>
    <description>Recent content in Vaccine Technology on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 14 Dec 2023 09:05:20 +0000</lastBuildDate><atom:link href="https://finan.club/tags/vaccine-technology/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Thu, 14 Dec 2023 09:05:20 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:40
Chances: AstraZeneca&amp;rsquo;s acquisition of Icosavax for $1.1 billion signals its strong interest in expanding its reach into cutting-edge vaccine technology with Icosavax&amp;rsquo;s innovative vaccine platform. The deal will provide AstraZeneca with a combination shot aimed at two respiratory viruses, which could be a significant opportunity for the company&amp;rsquo;s infectious disease division.</description>
    </item>
    
  </channel>
</rss>
